MedPath

Fluoxetine

Generic Name
Fluoxetine
Brand Names
Prozac, Sarafem, Symbyax
Drug Type
Small Molecule
Chemical Formula
C17H18F3NO
CAS Number
54910-89-3
Unique Ingredient Identifier
01K63SUP8D
Background

Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication

Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).

Associated Conditions
Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
Associated Therapies
Maintenance therapy

Fluoxetine Essay in Children With Autism

Phase 2
Withdrawn
Conditions
Autism
Interventions
Drug: placebo
Drug: fluoxetine
First Posted Date
2009-04-02
Last Posted Date
2012-01-10
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Registration Number
NCT00873834

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2009-02-24
Last Posted Date
2012-04-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
463
Registration Number
NCT00849693
Locations
🇲🇽

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalnepantla, Mexico

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2009-02-24
Last Posted Date
2017-09-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
337
Registration Number
NCT00849901
Locations
🇺🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

Phase 4
Completed
Conditions
Suicide
Borderline Personality Disorder
Interventions
First Posted Date
2009-02-03
Last Posted Date
2017-08-18
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
84
Registration Number
NCT00834834
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa

Not Applicable
Completed
Conditions
Eating Disorders
Interventions
Behavioral: Cognitive Behavioral Therapy
Drug: Fluoxetine
Behavioral: Guided Self-Help
First Posted Date
2008-08-13
Last Posted Date
2019-11-01
Lead Sponsor
University of Minnesota
Target Recruit Count
293
Registration Number
NCT00733525
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

University of Minnesota Minneapolis, MN, Minneapolis, Minnesota, United States

🇺🇸

University of North Dakota / Neuropsychiatric Research Institute, Fargo, North Dakota, United States

and more 1 locations

Fluoxetine vs. Brief Psychotherapy for Major Depression

Not Applicable
Completed
Conditions
Major Depressive Disorder
Interventions
Behavioral: Short-term psychodynamic psychotherapy
Drug: Fluoxetine
First Posted Date
2008-07-14
Last Posted Date
2008-07-14
Lead Sponsor
University of Turku
Target Recruit Count
85
Registration Number
NCT00714779

The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder

Phase 4
Completed
Conditions
Premenstrual Syndrome
Premenstrual Dysphoric Disorder
Interventions
First Posted Date
2008-05-15
Last Posted Date
2018-07-27
Lead Sponsor
University of Pennsylvania
Target Recruit Count
45
Registration Number
NCT00678574
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-05-12
Last Posted Date
2017-06-01
Lead Sponsor
University of Pennsylvania
Target Recruit Count
8
Registration Number
NCT00676026
Locations
🇺🇸

Yale University School of Medicine; Yale Program for Women's Reproductive Behavioral Health, New Haven, Connecticut, United States

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

First Posted Date
2008-04-25
Last Posted Date
2010-06-15
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
750
Registration Number
NCT00666757
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States

Fluoxetine on Motor Rehabilitation After Ischemic Stroke

Phase 2
Completed
Conditions
Ischemic Stroke
Motor Impairment
Interventions
Drug: placebo
Drug: fluoxetine
First Posted Date
2008-04-14
Last Posted Date
2011-09-16
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
100
Registration Number
NCT00657163
Locations
🇫🇷

University Hospital René Dubos, Cergy-Pontoise, France

🇫🇷

University Hospital Sainte Anne, Paris, France

🇫🇷

University Hospital Pitié Salpétrière, Paris, France

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath